Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders. We have a leading portfolio of hemophilia therapies and an innovative pipeline of programs in hemophilia, cold agglutinin disease, sickle cell disease and beta thalassemia.

We believe that great science conquers the toughest medical obstacles, and we are inspired to push scientific boundaries to make a meaningful impact in the lives of people with rare blood disorders. As an independent company formed by a spin-off of BiogenÍs hemophilia business in 2017, we bring a strong legacy of innovation, world-class science, and commitment to the blood disorders community. We are united by a singular purpose: to create progress where patients need it most.

With nearly 400 people and robust capabilities from discovery to commercialization, our vision is to become the leading hematology rare disease company.